Literature DB >> 21744786

Looking-glass synergistic pharmacological chaperones: DGJ and L-DGJ from the enantiomers of tagatose.

Sarah F Jenkinson1, George W J Fleet, Robert J Nash, Yuriko Koike, Isao Adachi, Akihide Yoshihara, Kenji Morimoto, Ken Izumori, Atsushi Kato.   

Abstract

The enantiomers of tagatose are converted to L-DGJ [a noncompetitive inhibitor of human lysosome α-galactosidase A (α-Gal A), K(i) 38.5 μM] and DGJ [a competitive inhibitor of α-Gal A, K(i) 15.1 nM] in 66% yield. L-DGJ and DGJ provide the first examples of pharmacological chaperones that (a) are enantiomeric iminosugars and (b) have synergistic activity with implications for the treatment of lysosomal storage disorders and other protein deficiencies.
© 2011 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21744786     DOI: 10.1021/ol201552q

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  10 in total

1.  Olefin Isomers of a Triazole Bisphosphonate Synergistically Inhibit Geranylgeranyl Diphosphate Synthase.

Authors:  Cheryl Allen; Sandhya Kortagere; Huaxiang Tong; Robert A Matthiesen; Joseph I Metzger; David F Wiemer; Sarah A Holstein
Journal:  Mol Pharmacol       Date:  2017-01-05       Impact factor: 4.436

Review 2.  Microbial and enzymatic strategies for the production of L-ribose.

Authors:  Ming Chen; Hao Wu; Wenli Zhang; Wanmeng Mu
Journal:  Appl Microbiol Biotechnol       Date:  2020-02-22       Impact factor: 4.813

Review 3.  Ion channels and pain in Fabry disease.

Authors:  Carina Weissmann; Adriana A Albanese; Natalia E Contreras; María N Gobetto; Libia C Salinas Castellanos; Osvaldo D Uchitel
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

4.  Host glycan sugar-specific pathways in Streptococcus pneumoniae: galactose as a key sugar in colonisation and infection [corrected].

Authors:  Laura Paixão; Joana Oliveira; André Veríssimo; Susana Vinga; Eva C Lourenço; M Rita Ventura; Morten Kjos; Jan-Willem Veening; Vitor E Fernandes; Peter W Andrew; Hasan Yesilkaya; Ana Rute Neves
Journal:  PLoS One       Date:  2015-03-31       Impact factor: 3.240

5.  Identification of an Allosteric Binding Site on Human Lysosomal Alpha-Galactosidase Opens the Way to New Pharmacological Chaperones for Fabry Disease.

Authors:  Valentina Citro; Jorge Peña-García; Helena den-Haan; Horacio Pérez-Sánchez; Rosita Del Prete; Ludovica Liguori; Chiara Cimmaruta; Jan Lukas; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  PLoS One       Date:  2016-10-27       Impact factor: 3.240

6.  N-Nonyloxypentyl-l-Deoxynojirimycin Inhibits Growth, Biofilm Formation and Virulence Factors Expression of Staphylococcus aureus.

Authors:  Eliana De Gregorio; Anna Esposito; Adriana Vollaro; Maria De Fenza; Daniele D'Alonzo; Antonella Migliaccio; Vita Dora Iula; Raffaele Zarrilli; Annalisa Guaragna
Journal:  Antibiotics (Basel)       Date:  2020-06-26

Review 7.  Pharmacological Chaperone Therapy for Pompe Disease.

Authors:  Marc Borie-Guichot; My Lan Tran; Yves Génisson; Stéphanie Ballereau; Cécile Dehoux
Journal:  Molecules       Date:  2021-11-29       Impact factor: 4.411

8.  An Amination-Cyclization Cascade Reaction for Iminosugar Synthesis Using Minimal Protecting Groups.

Authors:  Alex A Hunt-Painter; Benjamin M Deeble; Bridget L Stocker; Mattie S M Timmer
Journal:  ACS Omega       Date:  2022-08-10

Review 9.  Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations.

Authors:  Ludovica Liguori; Maria Monticelli; Mariateresa Allocca; Bruno Hay Mele; Jan Lukas; Maria Vittoria Cubellis; Giuseppina Andreotti
Journal:  Int J Mol Sci       Date:  2020-01-13       Impact factor: 5.923

Review 10.  Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis.

Authors:  Anna Esposito; Daniele D'Alonzo; Maria De Fenza; Eliana De Gregorio; Anna Tamanini; Giuseppe Lippi; Maria Cristina Dechecchi; Annalisa Guaragna
Journal:  Int J Mol Sci       Date:  2020-05-09       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.